Good News! SBK Selected for the “2022 Chengdu SME Growth Program Nurturing Enterprise”

We are excited to announce that SBK has been officially selected for the 2022 Chengdu SME Growth Program Nurturing Enterprises (Second Batch). SBK has been recognized as a “Proposed Enterprise Above Designated Size” after a rigorous assessment process.

Out of the 368 enterprises included in this year’s selection, SBK is among the 139 Proposed Enterprises Above Designated Size, and stands alongside 153 Growth Enterprises and 76 “Little Giant” Enterprises.

The Chengdu SME Growth Program is a strategic initiative focused on fostering the development of growth-oriented SMEs, centering on the “5+5+1” modern open industrial system, specifically those with promising prospects. It aims to support companies in becoming specialized, sophisticated, distinctive, and innovative, ultimately helping them become “future champions” in their sectors. The program also focuses on enterprises below designated size, guiding them toward becoming enterprises above designated size and leaders in their respective fields.

SBK, specializing in the R&D and commercialization of innovative drugs for diseases such as cardiovascular and cerebrovascular conditions, has made remarkable progress in recent years. This recognition reflects not only the company’s achievements but also our unwavering confidence and determination to grow into an enterprise above designated size and impactful enterprise.

Empowering Better Health Through Inclusive Care and Support. SBK remains committed to intensifying our R&D efforts, driving innovation in drug development, and strengthening our core competitiveness. We will continue to contribute to the high-quality economic development of the region.